Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 12, 1982 - Issue 4
14
Views
7
CrossRef citations to date
0
Altmetric
Research Article

The excretion of metabolites of the D-glucuronic acid pathway in human urine.: Effect of phenobarbitone administration

, , , &
Pages 241-247 | Received 27 Dec 1981, Published online: 22 Sep 2008
 

Abstract

1. The urinary excretion of four metabolites of the D-glucuronic acid pathway, namely D-glucaric acid, free (unconjugated) D-glucuronic acid, L-gulonic acid and xylitol, has been studied in normal male volunteers and in male and female epileptic patients receiving phenobarbitone anticonvulsant therapy.

2. In normal male subjects the urinary excretion of the D-glucuronic acid metabolites, expressed per unit of creatinine, was similar in first void and total (24 h) urine samples and was fairly constant over a period of 4 weeks.

3. In male and female epileptic patients phenobarbitone treatment enhanced the urinary excretion of D-glucaric acid and xylitol and the combined excretion of D-glucaric acid, L-gulonic acid and xylitol.

4. It is suggested that the measurement of a spectrum of urinary D-glucuronic acid metabolites may provide a more reliable index for assessment of the induction of hepatic xenobiotic-metabolizing enzyme activities in man than the determination of urinary D-glucaric acid alone.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.